OT mobile menu

Search form


Lung Cancer Targets

Study Identifies How Lung Tumors Acquire Immunotherapy Resistance

NSCLC can acquire resistance to immune checkpoint blockade agents through evolutionary culling of tumor clones harboring the mutations for cell surface neoantigens that are recognized by patients’ immune T cells. Image © Tashatuvango/ Shutterstock.com

Image © koya979 / Shutterstock.com

Lung Cancer Targets

A case study from the University of Colorado suggests that traditional gene testing for NSCLC patients may not be sufficient for detecting potential oncogenic drivers.

Circulating tumor cells isolated from early stages of lung cancer may be predictive of poor prognosis and could potentially be predictive biomarkers of disease recurrence.

ASCO is issuing a new clinical practice guideline that clarifies the role of immunotherapy in the treatment of patients with advanced non–small-cell lung cancer.

Increases in the TP53 mutation in African American men with tobacco-related cancers may be responsible for chemotherapy resistance and a poorer prognosis overall.

Osimertinib demonstrated clinically meaningful progression-free survival benefit in EGFR mutation–positive NSCLC compared with current standard of care.

Researchers in Spain discovered a strange side effect of PD-L1 immunotherapy in some NSCLC patients—hair repigmentation—that may be a good response marker for this treatment.

A subpopulation of T cells called tissue resident memory cells may be able to determine which cancer patients' immune systems can mount an effective anti-tumor response


Subscribe to Lung Cancer Targets on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.